Navigation Links
Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
Date:1/4/2011

onducting the study at sites within and outside the United States.

Naive Arm

Approximately 100 treatment-naive HCV patients are expected to receive ANA598 in combination with SOC and 33 treatment-naive HCV patients are to receive placebo plus SOC.  Treatment duration for naive patients will be response-guided; patients who achieve undetectable levels of virus at Week 8 and maintain undetectable levels of virus will be scheduled to conclude all treatment at Week 28.  For naive patients with detectable virus at Week 8 dosing with ANA598, or placebo, and SOC is planned to continue through Week 48.  The Company expects to receive Week 8 antiviral response data by the end of the second quarter of 2011, Week 12 antiviral response data in the third quarter of 2011 and Week 24 antiviral response data in the fourth quarter of 2011.

Treatment-Experienced Arm, Including Prior Null Responders

Approximately 80 patients who were partial responders during, or relapsers after, a prior course of therapy with SOC alone are expected to receive ANA598 in combination with SOC, and 33 corresponding patients are to receive placebo plus SOC.  Additionally, approximately 28 prior null responder patients are to receive ANA598 in combination with SOC.  All treatment-experienced patients who receive ANA598 are scheduled to receive triple combination therapy for 48 weeks.  For the treatment-experienced patients, the Company expects to receive Week 12 antiviral response data in the third quarter of 2011 and Week 24 antiviral response data in the fourth quarter of 2011.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable wit
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
2. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
3. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
4. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
6. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
7. Anadys Retains Lazard as Strategic Advisor
8. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
9. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 The Brandeis Medical Center, led by Dr. ... premier and affordable laser tattoo removal experience with the advanced Astanza ... in providing high quality cosmetic services with cutting edge medical technology ... Southern California has seen a dramatic increase in ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at 165 ... the first in Loudoun County to receive ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian of ... Taylor , are avid scuba divers. "As altitude skiers and hikers, ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), a ... in respiratory critical care, will hold a conference call ... its March 6th announcement that SURFAXIN (lucinactant) has been ... Distress Syndrome (RDS) in premature infants at high risk ...
Cached Medicine Technology:Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN® (lucinactant) 2
(Date:4/18/2014)... of your worst memories? How did it make you ... a negative personal experience, such as how sad you ... emotional distress, especially when you can,t stop thinking about ... thinking about the context of the memories, rather than ... way to alleviate the negative effects of these memories, ...
(Date:4/18/2014)... ― A new study in the American Journal ... Google searches reveals a recurring pattern that could be ... Investigators from San Diego State University, the Santa Fe ... "healthy" Google searches (searches that included the term healthy ... the U.S. from 2005 to 2012. They found that ...
(Date:4/17/2014)... of chronic inflammation in benign prostate tissue was ... this association was found even in those with ... study published in Cancer Epidemiology, Biomarkers & ... for Cancer Research. , An analysis of prostate ... placebo arm of the Prostate Cancer Prevention Trial ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... the Hebrew University of Jerusalem have discovered that Vav1 ... one of the factors in tumorous tissue growth -- plays ... previously been thought. The discovery has implications for further concentration ... work of the researchers, led by Dr. Shulamit Katzav-Shapira of ...
... 2010) International experts and scientists will present ... life of stockpiled drugs to identifying unlabeled substances ... of the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical ... American Association of Pharmaceutical Scientists (AAPS) Annual Meeting ...
... , MONDAY, Nov. 8 (HealthDay News) -- A new ... can be inherited. As part of the Framingham Foot ... participants between 2002 and 2005, researchers studied 675 people ... towards the smaller toes (known as hallux valgus), and 154 ...
... an electrical switch allows the flow of electricity into electrical ... optical switch allowing the flow of light through otherwise opaque ... Los Alamos National Laboratory delivers a 200 terawatt power pulse ... States) in half a trillionth of a second (picosecond) time. ...
... study suggests joint complaints attributed to aromatase inhibitors (AI), ... arthritis or autoimmune disease. Because of that, researchers ... of arthritis should be encouraged to continue taking the ... Tuesday, Nov. 9 at the 74th Annual Scientific Meeting ...
... GA Lupus puts children at higher risk for ... using statins doesn,t provide enough benefit to warrant their ... largest study of pediatric lupus patients to date. ... and organ damage. Children with lupus show early signs ...
Cached Medicine News:Health News:Hebrew University researchers discover expanded role for cancer-causing gene 2Health News:Common Foot Disorders Can Be Inherited, Research Shows 2Health News:Plasma as a fast optical switch 2Health News:Joint pain linked to breast cancer drug not inflammatory arthritis or autoimmune disease 2Health News:Statins don't prove useful for general pediatric lupus population 2
Eliminate preanalytical errors with automated QC module....
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
... Submit your analyzer data via the ... a worldwide peer group. , ... you to perform statistical analysis of ... often as you like. Peer-group data ...
Automated QC module...
Medicine Products: